Influence of Bayesian optimization on the performance of propofol target-controlled infusion.

BACKGROUND: Target controlled infusion (TCI) systems use population-based pharmacokinetic (PK) models that do not take into account inter-individual residual variation. This study compares the bias and inaccuracy of a population-based vs a personalized TCI propofol titration using Bayesian adaptation. Haemodynamic and hypnotic stability, and the prediction probability of alternative PK models, was studied. METHODS: A double-blinded, prospective randomized controlled trial of 120 subjects undergoing cardiac surgery was conducted. Blood samples were obtained at 10, 35, 50, 65, 75 and 120 min and analysed using a point-of-care propofol blood analyser. Bayesian adaptation of the PK model was applied at 60 min in the intervention group. Median (Absolute) Performance Error (Md(A)PE) was used to evaluate the difference between bias and inaccuracy of the models. Haemodynamic (mean arterial pressure [MAP], heart rate) and hypnotic (bispectral index [BIS]) stability was studied. The predictive performance of four alternative propofol PK models was studied. RESULTS: MdPE and MdAPE did not differ between groups during the pre-adjustment period (control group: 6.3% and 16%; intervention group: 5.4% and 18%). MdPE differed in the post-adjustment period (12% vs. -0.3%), but MdAPE did not (18% vs. 15%). No difference in heart rate, MAP or BIS was found. Compared with the other models, the Eleveld propofol PK model (patients) showed the best prediction performance. CONCLUSIONS: When an accurate population-based PK model was used for propofol TCI, Bayesian adaption of the model improved bias but not precision. CLINICAL TRIAL REGISTRATION: Dutch Trial Registry NTR4518.

Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts.

This review discusses the ways in which anaesthetists can optimize anaesthetic-analgesic drug administration by utilizing pharmacokinetic and pharmacodynamic information. We therefore focus on the dose-response relationship and the interactions between i.v. hypnotics and opioids. For i.v. hypnotics and opioids, models that accurately predict the time course of drug disposition and effect can be applied. Various commercial or experimental drug effect measures have been developed and can be implemented to further fine-tune individual patient-drug titration. The development of advisory and closed-loop feedback systems, which combine and integrate all sources of pharmacological and effect monitoring, has taken the existing kinetic-based administration technology forwards closer to total coverage of the dose-response relationship.

IGF-I gene transfer in thermally injured rats.

Exogenous insulin-like growth factor-I (IGF-I) is known to improve the pathophysiology of a thermal injury, however, deleterious side-effects have limited its utility. Cholesterol-containing cationic liposomes that encapsulate complementary DNA (cDNA) are nonviral carriers used for in vivo gene transfection. We propose that liposome IGF-I gene transfer will accelerate wound healing in burned rats and attenuate deleterious side-effects associated with high levels of IGF-I. To test this hypothesis IGF-I gene constructs, encapsulated in liposomes, were studied for their efficacy in modulating the thermal injury response. Thirty adult male Sprague-Dawley rats were given a 60% TBSA scald burn and randomly divided into three groups to receive weekly subcutaneous injections of liposomes plus the lacZ gene coding for beta-galactosidase, liposomes plus cDNA for IGF-I and beta-galactosidase or liposomes plus the rhIGF-I protein. Body weights and wound healing were measured. Muscle and liver dry/wet weights and IGF-I concentrations in serum, skin and liver were measured by radioimmunoassay. Transfection was confirmed by histochemical staining for beta-galactosidase. Rats receiving the IGF-I cDNA constructs exhibited the most rapid wound re-epithelialization and greatest increase in body weight and gastrocnemius muscle protein content (P < 0.05). Local IGF-I protein concentrations in the skin were higher when compared to liposomes containing only the lacZ gene (P < 0.05) Transfection was apparent in the cytoplasm of myofibroblasts, endothelial cells and macrophages of the granulation tissue. Liposomes containing the IGF-I gene constructs proved effective in preventing muscle protein wasting and preserving total body weight after a severe thermal injury.

Recombinant human growth hormone alters acute phase reactant proteins, cytokine expression, and liver morphology in burned rats.

BACKGROUND: The effects of exogenous recombinant human growth hormone (rhGH) on hepatic acute phase reactant proteins, cytokine expression, and liver morphology were studied in thermally injured rats to define whether rhGH alters the acute phase response. MATERIALS AND METHODS: Sprague-Dawley rats (56 males) receiving a 60% TBSA third-degree scald burn were randomly divided into two groups to receive either 2.5 mg/kg/day sc rhGH or saline. Rats were sacrificed on Postburn Days 1, 2, 5, and 7. Serum acute phase reactant proteins and cytokines TNF-alpha, IL-1alpha, IL-1beta, and IL-6 were measured. Hepatocyte proliferation, hepatic cytokine gene expression, and liver protein concentrations were determined. RESULTS: Recombinant hGH increased serum albumin on Days 5 and 7 after burn (P < 0.05). Serum haptoglobin and alpha1-acid glycoprotein levels decreased at 2, 5, and 7 days after burn compared to saline (P < 0.05). In rats treated with rhGH, serum IL-1beta decreased 1 day postburn, while serum TNF-alpha increased 5 days after burn compared to saline (P < 0.05). Serum IL-6 and IL-1alpha did not change. Hepatic RNA levels for TNF-alpha were significantly elevated on Day 1 postburn compared to saline (P < 0. 05). Hepatic protein content increased on Days 2, 5, and 7 postburn compared to saline (P < 0.05). Hepatocyte proliferation in rhGH-treated rats increased on Day 5 after burn (P < 0.05). CONCLUSION: Data indicate that rhGH alters the hepatic acute phase response by decreasing type I acute phase proteins and modulating IL-1-like cytokine expression. These changes are associated with increased hepatocyte mitosis and serum and total liver protein concentrations.